Abstract: The invention provides novel quinoline sulfonamide compounds of Formula I: and their use for the treatment or prevention of bacterial infections caused by both Gram positive and Gram negative bacteria such as, for example, infections caused by one or more bacteria from the Enterobactericeae, Staphylococcaceae, or Streptococcaceae families. The compounds described and claimed herein may be formulated in one or more pharmaceutical or veterinary compositions for use in animal husbandry, and in particular in relation to the treatment of mastitis by directly targeting mastitis causing bacteria in a bovine herd. In certain embodiments described herein the pharmaceutical or veterinary compositions are formulated as a spray for direct administration to the udder of the bovine animal such as a cow.

Abstract: The invention provides novel quinoline sulfonamide compounds of Formula I: and their use for the treatment or prevention of bacterial infections caused by both Gram positive and Gram negative bacteria such as, for example, infections caused by one or more bacteria from the Enterobactericeae, Staphylococcaceae, or Streptococcaceae families. The compounds described and claimed herein may be formulated in one or more pharmaceutical or veterinary compositions for use in animal husbandry, and in particular in relation to the treatment of mastitis by directly targeting mastitis causing bacteria in a bovine herd. In certain embodiments described herein the pharmaceutical or veterinary compositions are formulated as a spray for direct administration to the udder of the bovine animal such as a cow.

Abstract: A brush assembly adapted to be mounted to a drain. The drain brush assembly (11) comprises a housing (14), a brush head (16) and a set of bristles (51). The housing is adapted to be engaged with a drain to provide the inlet to the drain. The brush head (16) is supported by the housing to extend across the drain inlet. The set of bristles (51) extends from the outermost axial face of the brush head (16). The brush head (16) is supported by the housing (14) to be resiliently depressible into the housing (14).

Abstract: The present invention relates to treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs and other altered antibodies such as Fabs, chimeric, human and humanized antibodies that do not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor.